Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 526,265
  • Shares Outstanding, K 36,095
  • Annual Sales, $ 1,520 K
  • Annual Income, $ -56,050 K
  • 60-Month Beta 1.83
  • Price/Sales 346.20
  • Price/Cash Flow N/A
  • Price/Book 8.24
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.88
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.48
  • Number of Estimates 4
  • High Estimate -0.42
  • Low Estimate -0.52
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -2.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.01 +4.07%
on 06/29/20
18.17 -19.76%
on 06/05/20
-2.18 (-13.01%)
since 06/02/20
3-Month
8.72 +67.20%
on 04/03/20
21.97 -33.64%
on 05/19/20
+4.84 (+49.69%)
since 04/02/20
52-Week
5.35 +172.52%
on 11/08/19
21.97 -33.64%
on 05/19/20
+5.55 (+61.46%)
since 07/02/19

Most Recent Stories

More News
iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair

, /PRNewswire/ -- iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, today announces that it has appointed Dr. ...

SNDX : 14.58 (+0.21%)
ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN)...

SNDX : 14.58 (+0.21%)
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 14.58 (+0.21%)
Portage is pleased to announce the appointment of Allan L. Shaw as CFO

, /PRNewswire/ - Portage Biotech Inc. (PBT.U: CSE, PTGEF: OTC Markets) ("Portage" or the "Company") a leader in the early stage immune oncology space announced today the appointment of to Chief Financial...

NEWLF : 0.0001 (unch)
PTGEF : 0.1100 (-6.86%)
SNDX : 14.58 (+0.21%)
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 14.58 (+0.21%)
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 14.58 (+0.21%)
HTGC : 10.42 (+0.97%)
Syndax Announces Pricing of Public Offering of Common Stock

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.58 (+0.21%)
Syndax Announces Pricing of Public Offering of Common Stock

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.58 (+0.21%)
Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.58 (+0.21%)
Syndax Announces Proposed Public Offering of Common Stock

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.58 (+0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SNDX with:

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

2nd Resistance Point 15.30
1st Resistance Point 14.94
Last Price 14.58
1st Support Level 14.13
2nd Support Level 13.68

See More

52-Week High 21.97
Fibonacci 61.8% 15.62
Last Price 14.58
Fibonacci 50% 13.66
Fibonacci 38.2% 11.70
52-Week Low 5.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar